MLL rearrangements emerge during spontaneous apoptosis of clinical blood samples.
Basecke
J
J
Karim
K
K
Podleschny
M
M
Becker
A
A
Glass
B
B
Trumper
L
L
Griesinger
F
F
D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics*; D016477:Artifacts; D015331:Cohort Studies; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000187:drug effects / Q000235:genetics*; D011446:Prospective Studies; D013048:Specimen Handling; D013997:Time Factors; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D051788:Myeloid-Lymphoid Leukemia Protein